Weekly recaps, case studies, and the trading frameworks that separate informed traders from the crowd.
KOD +72%. MAZE -33% despite positive data. Six catalysts, every possible outcome.
Peak sales estimates, revenue runways, and the financial anatomy of a blockbuster drug.
The MAZE case study: +22% pre-market, -33% by close. Here's why.